e8vk
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2006
CYTOKINETICS, INCORPORATED
(Exact name of registrant as specified in its charter)
         
DELAWARE   000-50633   94-3291317
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of incorporation)       Identification No.)
280 East Grand Avenue
South San Francisco, California 94080

(Address of principal executive offices, including zip code)
650-624-3000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


TABLE OF CONTENTS

ITEM 8.01. OTHER EVENTS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1


Table of Contents

ITEM 8.01. OTHER EVENTS.
     On October 2, 2006, Cytokinetics, Incorporated issued a press release announcing the presentation of Phase II clinical trial data at the Annual Meeting of the European Society of Medical Oncology for its drug candidates ispinesib (SB-715992) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. This clinical trial was being conducted by the National Cancer Institute. A copy of this press release is being filed with this Current Report on Form 8-K, as Exhibit 99.1, and is hereby incorporated by reference into this Item 8.01.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
     The following Exhibit is filed as part of this Current Report on Form 8-K:
     
Exhibit No.
  Description
 
99.1
  Press Release, dated October 2, 2006.

2


Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  CYTOKINETICS, INCORPORATED
 
 
  By:   /s/ Sharon Surrey-Barbari    
    Sharon Surrey-Barbari   
    Senior Vice President, Finance and Chief
Financial Officer
 
 
 
Date: October 2, 2006

3


Table of Contents

EXHIBIT INDEX
     
Exhibit No.
  Description
 
99.1
  Press Release, dated October 2, 2006.